GlassScriptPhysician profile
Kristopher E Medina
NPI 1124416185
$9,422.27
in general payments reported to CMS, 2019-2025
21 companies · $2,109 in 2025
The $2,109 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,013 · 2022: $1,496 · 2023: $2,151 · 2024: $2,654 · 2025: $2,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,551 · Consulting Fee: $1,135 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,550.75 |
| Consulting Fee | $1,135.00 |
| Education | $227.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,559.99 | 2021-2025 | |
| Lundbeck LLC | $1,040.55 | 2023-2025 | Vyepti |
| Pfizer INC. | $993.58 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $789.50 | 2021-2025 | Ajovy, Austedo Xr, Austedo |
| Lilly USA, LLC | $513.99 | 2021-2025 | Emgality, Reyvow |
| Impel Pharmaceuticals INC. | $454.68 | 2022-2023 | Trudhesa |
| Biohaven Pharmaceuticals, INC. | $416.82 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $412.12 | 2022 | |
| Amgen INC. | $310.44 | 2021-2023 | Aimovig |
| Upsher-Smith Laboratories LLC | $299.42 | 2021-2023 | |
| Allergan, INC. | $249.96 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $91.98 | 2023-2024 | Ztlido |
| Ipsen Biopharmaceuticals, INC | $72.82 | 2023-2025 | Dysport |
| Collegium Pharmaceutical, INC. | $44.77 | 2022 | |
| Impel Pharmaceuticals LLC | $38.58 | 2024-2025 | Trudhesa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $37.10 | 2025 | Symbravo |
| Tonix Medicines, INC. | $28.69 | 2024 | Zembrace Symtouch |
| Biogen, INC. | $22.03 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.99 | 2023 | Quviviq |
| Amneal Pharmaceuticals LLC | $14.22 | 2021 | |
| Supernus Pharmaceuticals, INC. | $13.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristopher Medina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.